| 刘华丽,熊小明,彭 敏.免疫检测点抑制剂的免疫相关性毒副作用的治疗与管理[J].肿瘤学杂志,2017,23(5):428-432. |
| 免疫检测点抑制剂的免疫相关性毒副作用的治疗与管理 |
| Management and Treatment of Immune-related Adverse Events with Immune Checkpoint Inhibitors |
| 投稿时间：2016-06-23 |
| DOI：10.11735/j.issn.1671-170X.2017.05.B015 |
|
 |
| 中文关键词: 免疫检测点抑制剂 免疫相关性不良反应 细胞毒性T淋巴细胞抗原-4 程序性细胞死亡-1 |
| 英文关键词:immune checkpoint inhibitors immune-related adverse events (irAEs) cytotoxic T-lymphocyte antigen 4 programmed celldeath-1 |
| 基金项目:国家自然科学基金（81372407） |
|
| 摘要点击次数: 2072 |
| 全文下载次数: 658 |
| 中文摘要: |
| 摘 要：近年来，免疫检测点抑制剂在包括肺癌、肾透明细胞癌、黑色素瘤等多种肿瘤中取得惊人疗效。尽管免疫检测点抑制剂在肿瘤治疗中取得显著疗效，但免疫检测点抑制剂的非特异性免疫激活导致的免疫相关性不良反应可直接影响治疗的进展，甚至威胁患者生命。因此，有效管理免疫相关性不良反应，减少3~4级治疗相关性不良事件的发生，对于免疫治疗疗效至关重要。全文将从临床表现、发病率及临床治疗三方面综述抗细胞毒性T淋巴细胞抗原-4(cytotoxic T-lymphocyte antigen 4，CTLA-4)以及程序性细胞死亡-1 (programmed cell death-1，PD-1)单克隆抗体药物的常见免疫相关性不良反应。 |
| 英文摘要: |
| Abstract：In recent years，immune checkpoint inhibitors have shown impressive clinical activity in a variety of tumors，including lung cancer，renal clear cell carcinoma，melanoma，and so on. Despite achieving great clinical success， these drugs can active immune response non-specially，induce a unique set of immune-related adverse events(irAEs) that can interrupt the anti-tumor treatment and be even fatal. Therefore，the effective management of irAEs and reducing the occurrence of grade 3-4 treatment-related adverse events are critical in optimizing treatment outcomes. This review focuses on the clinical manifestations，morbidity of more common irAEs of anti-CTLA-4 or PD-1monoclonal antibody drugs and provides a suggested approach for management of specific irAEs. |
|
在线阅读
查看全文 查看/发表评论 下载PDF阅读器 |